Replimune Group Inc. stocks have been trading up by 80.34 percent amid strong sentiment around its latest cancer therapy progress.
Click Here for a Millionaire's POV on Trading REPL
SUBSCRIBE FOR ALERTSJOIN 50,000+ ACTIVE TRADERS
Key Takeaways
- Shares spiked after reports that President Trump approved a plan to fire FDA Commissioner Marty Makary, who was tied to the rejection of Replimune’s RP1 melanoma therapy.
- The RP1 rejection was controversial because it conflicted with a positive review panel recommendation and support from melanoma specialists.
- Makary later resigned over a clash with the administration on fruit-flavored e‑cigarettes; food chief Kyle Diamantas stepped in as acting commissioner.
- Large-cap pharma and multiple biotech names, including REPL, are now in focus as traders reassess the FDA’s stance under new leadership.
Live Update At 10:02:44 EDT: On Friday, May 29, 2026 Replimune Group Inc. stock [NASDAQ: REPL] is trending up by 80.34%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.
Quick Financial Overview
Replimune Group Inc. (REPL) looks like a classic high-risk, high-reward biotech setup right now. On the tape, REPL just staged a massive breakout. The stock closed at $4.68 on 2026/05/28, then ripped to $8.515 on 2026/05/29. That’s an intraday move of more than 80%, driven by the FDA leadership shock tied to its RP1 melanoma therapy story.
Zooming into the 5‑minute chart, REPL exploded out of the gate from the premarket $4s and $6s, spiking through $7, then $8, and touching highs near $8.77. That’s textbook momentum for traders who focus on fast moves and tight risk control.
More Breaking News
- EWBC Jumps As East West Bank Lands AXS Partnership
- ELVN Stock Jumps As FDA Clears Path For Phase 3 ENABLE Trial
- Enliven Therapeutics Stock Surges On ELVN-001 Breakthrough And $400M Raise
- Albemarle Stock Jumps As Analysts Hike Price Targets
Under the hood, Replimune is still a development‑stage biotech. The latest quarterly numbers show revenue is effectively zero, with a net loss of about $70.9M and operating cash burn around $65.9M. REPL holds roughly $124.7M in cash and $269.1M when you include short‑term investments, plus a strong current ratio of 5.6. That tells traders REPL has runway to keep funding trials, but negative returns on equity and assets flag heavy spending and ongoing dilution risk. It’s a story stock, not a value name.
Why Traders Are Watching REPL After The FDA Shake-Up
REPL is back on every biotech day-trader’s screen because the narrative just flipped. Replimune shares jumped after word that President Trump approved a plan to fire FDA Commissioner Marty Makary, the same official tied to the agency’s controversial rejection of REPL’s RP1 melanoma therapy.
Traders remember that RP1 wasn’t a clean “no” in the usual sense. The drug had already received a positive initial review panel recommendation and backing from melanoma specialists. When the FDA still shut it down, the decision looked political and inconsistent, not just scientific. That’s why the removal — and then resignation — of Makary matters so much to Replimune Group Inc.
The market is now pricing in a possible reset. A new acting commissioner, Kyle Diamantas, steps in with the FDA under pressure on multiple fronts, from cancer drugs to fruit‑flavored e‑cigarettes. Large‑cap pharma names are being reevaluated, but it’s smaller biotechs like REPL where regulatory mood shifts can move the stock 50%–100% in a single session.
For traders, this is about perception, not any new approval. There is no fresh RP1 decision on the table. But the belief that prior leadership may have been an outlier gives REPL’s pipeline story fresh life. The tape confirms that: huge range, heavy volume, and strong closes near the high of day. That kind of action attracts momentum traders who live on catalysts, gaps, and volatility.
Conclusion
REPL now sits at the crossroads of politics, science, and trading psychology. Replimune’s balance sheet shows real cash, a solid working capital position, and the ability to keep pushing the RP1 program and broader pipeline. At the same time, the income statement reminds traders that this is a company burning over $60M in cash per quarter with no commercial revenue yet. Every big move in REPL is fueled by headlines and hope, not earnings.
The FDA saga around RP1 adds another layer. The earlier positive panel and specialist backing showed that RP1 had credible scientific support. The later rejection created a cloud over Replimune Group Inc., and many traders simply walked away. Now, with Makary out and Diamantas in as acting commissioner, that cloud looks thinner. But it is not gone. There is still no guarantee the RP1 outcome changes.
For active traders, the lesson is to respect both the upside and the downside in REPL. The recent run from the $3s to the $8s shows how fast sentiment can flip when the story shifts. As Tim Sykes likes to say, “Trade the ticker, not the story — patterns repeat, but you must cut losses quickly.” In the same spirit of disciplined trading, and especially in a name like REPL where headlines and regulatory shifts can spark extreme moves, emotion has to stay out of the process; as Tim Bohen, lead trainer with StocksToTrade says, “The best trades are the ones you can make without emotion. Plan it, then execute it as if it’s routine.”. With Replimune, the pattern today is high volatility around a shifting regulatory backdrop, and that demands strict risk management and disciplined exits. This is educational and research content only, not a signal to buy or sell.
This is stock news, not investment advice. StocksToTrade News delivers real-time stock market updates tailored to highlight the key catalysts driving short-term price movements. Our coverage is designed for active traders and investors who thrive in fast-moving markets, with a focus on volatile sectors like penny stocks, AI stocks, Robinhood stocks and other momentum plays. From earnings reports and FDA approvals to mergers, new contracts, and unusual trading volume, we break down the events that can spark significant price action.
Looking to level up your trading game? Explore StocksToTrade, the ultimate platform for traders. With powerful tools designed for swing and day trading, integrated news scanning, and even social media monitoring, StocksToTrade keeps you one step ahead.
Check out our quick startup guide for new traders!
- How to Read Stock Charts: A Guide for Beginners
- Trading Plan: 6 Steps to Create One
- How To Create a Stock Watchlist
Ready to build your watchlists? Check out these curated lists:
Once your watchlist is set, take the next step and trade with confidence using StocksToTrade’s robust platform. Don’t miss out — grab your 14-day trial for just $7 and experience the edge you need to thrive in today’s fast-paced markets.